BIYELA STUDY

BIYELA: Bexsero Immunisation in Young Women in Africa. The BIYELA Study is a Phase 3 randomized, double-blinded, placebo-controlled trial evaluating the efficacy of the meningococcal serogroup B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection among individuals born female in South Africa. This study focuses on sexually transmitted infection (STI) prevention, with the primary goal of determining whether the Bexsero vaccine can effectively prevent cervical and/or anorectal gonococcal infections.

Study Objectives

The primary objective of the BIYELA Study is to assess whether the Bexsero vaccine, that is used for preventing meningococcal meningitis, can also play a role in preventing gonorrhea, a common STI that can lead to severe health complications, including pelvic inflammatory disease (PID), chronic pelvic pain, pregnancy complications and increase risk of HIV. The study will gather critical data on the vaccine’s efficacy and safety in this context, providing insights that could significantly impact STI prevention strategies in South Africa and globally.

Investigators

• Prof Sinead Delany-Moretlwe
• Dr Nicole Poovan

Latest Update

August 2024

For more information about the Biyela Study, contact us at 076 840 1106 or connect with us via WhatsApp or Please Call Me. We look forward to hearing from you. For additional details, you can also email us at rhicomms@wrhi.ac.za